Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Renner, W; Langsenlehner, U; Krenn-Pilko, S; Eder, P; Langsenlehner, T.
BCL2 genotypes and prostate cancer survival.
Strahlenther Onkol. 2017; 193(6):466-471 Doi: 10.1007/s00066-017-1126-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Renner Wilfried
Co-Autor*innen der Med Uni Graz
Krenn-Pilko Sabine
Langsenlehner Tanja
Langsenlehner Uwe

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

The antiapoptotic B‑cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality. The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients. During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10-4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58-3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05-3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51-3.36; p < 0.001). This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Alleles -
Androgen Antagonists - therapeutic use
Combined Modality Therapy -
Follow-Up Studies -
Genotype -
Homozygote -
Humans -
Kaplan-Meier Estimate -
Male -
Middle Aged -
Neoadjuvant Therapy -
Neoplasm Grading -
Neoplasm Staging -
Polymorphism, Single Nucleotide - genetics
Proportional Hazards Models -
Prostatic Neoplasms - genetics
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Proto-Oncogene Proteins c-bcl-2 - genetics
Radiotherapy Dosage -
Radiotherapy Planning, Computer-Assisted -
Radiotherapy, Conformal -
Survival Analysis -

Find related publications in this database (Keywords)
© Med Uni Graz Impressum